Best Cannabis Stocks of 2017

Caution: we are not professionals and high, so any investment made on our advice alone is deemed by us to be risky, unprofitable, dangerous, hopefully not illegal, and comes with a 100% lack of any sort of guarantee that you will make any money at all. Now that we’ve said our legal piece of mind, let’s step into the wild world of cannabis stocks. The following stocks of cannabis-related companies are the most stable and profitable over the long term, depending on a number of factors.

Factors that can effect a cannabis stock price:

  • Legal issues with the company or product/service locations
  • Investment or acquisition by a larger company
  • Growth or loss of sales/revenue
  • Number of shares available (volume) and shares volume being traded
  • A butterfly flaps its wings in Alaska and effects worldwide stock patterns


Best of 2017 Cannabis Stocks for Investment

GW Pharmaceuticals (NASDAQ: GWPH)

Epidiolex is GW’s lead cannabinoid product candidate and is a proprietary oral solution of pure plant-derived cannabidiol, or CBD. GW’s Epidiolex development is initially concentrating on severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS).

Aphria, Inc. (TSX-V: APH)

Aphria is the first public licensed medical cannabis producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters. Aphria is a Health Canada Licensed Producer of medical cannabis products. Cool fact: their medical cannabis is 100% greenhouse grown.

Canopy Growth Corporation (TSX-V: CGC)

With three core brands, they are positioning themselves as a diversified yet well connected company, with relationships including Snoop Dogg and DNA Genetics. Their three brands are Tweed, Bedrocan Canada, and Mettrum.

INSYS Therapeutics (NASDAQ: INSY)

INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems for therapeutic molecules that improve the quality of patients’ lives. Using proprietary sublingual spray technology and our capabilities to develop pharmaceutical cannabinoids, we work to address the clinical shortcomings of existing commercial products.

Kaya Holdings (OTC: KAYS)


Remember investing is risky, and you shouldn’t invest until you have 6 months of emergency savings etc. Due to the nature of the cannabis industry, and it’s slow legal growth, don’t expect huge short term gains, and think of the long term (3-5+ years)  If you’re looking to optimize your saving and investing strategies, we highly recommend reading and posting to the Personal Finance Subreddit.

Justin Meerkat

Cannabis Entrepreneur & Cofounder | Follow @justinmeerkat on Instagram

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.